Home » Stocks » ODT

Odonate Therapeutics, Inc. (ODT)

Stock Price: $20.22 USD 0.78 (4.01%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $20.30 +0.08 (0.40%) Jan 22, 7:51 PM
Market Cap 779.31M
Revenue (ttm) n/a
Net Income (ttm) -121.92M
Shares Out 32.82M
EPS (ttm) -3.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $20.22
Previous Close $19.44
Change ($) 0.78
Change (%) 4.01%
Day's Open 19.27
Day's Range 19.15 - 20.30
Day's Volume 190,234
52-Week Range 13.00 - 45.63

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 weeks ago

Odonate has only one drug, an oral version of well-known chemo drugs called taxanes. Its Phase 3 trial was solid, but the market may have misunderstood the data.

Seeking Alpha - 2 weeks ago

Odonate is a small biotech attempting to win approval for Tesetaxel, a chemotherapy treatment indicated for treatment of HER2 negative metastatic breast cancer. The company's share price nose ...

Benzinga - 3 weeks ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...

Other stocks mentioned: DNMR, LNG, CQP, FNF, IEP, IQV, SPLP
Benzinga - 4 weeks ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...

Other stocks mentioned: FL, GME, NTAP, ARVN, BCAB, COUP, EOSE, GWRE, JKHY, MBIO, UPST, VST
Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best‑in‑class therapeutics that improve and extend the lives of p...

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of p...

Business Wire - 1 month ago

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of p...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 16, 2020) -  The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Odonate Therapeutics, Inc. (N...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - November 16, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odon...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 16, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired secu...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 16, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) b...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - November 15, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odona...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 14, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) b...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - November 13, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Odonate Therapeutics, Inc. (...

PRNewsWire - 2 months ago

NEW YORK, Nov. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, ...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - November 12, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odona...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - November 11, 2020) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odona...

Newsfile Corp - 2 months ago

Los Angeles, California--(Newsfile Corp. - November 10, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Odon...

PRNewsWire - 2 months ago

NEW YORK, Oct. 31, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Odonate Therapeutics, Inc. ("Odonate" or the "Company") (NASDAQ: ODT) and cer...

Newsfile Corp - 2 months ago

New York, New York--(Newsfile Corp. - October 30, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) b...

PRNewsWire - 2 months ago

NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, ...

Business Wire - 2 months ago

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of p...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 23, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) be...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 15, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) b...

PRNewsWire - 3 months ago

NEW YORK, Oct. 12, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, ...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 9, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) bet...

Newsfile Corp - 3 months ago

New York, New York--(Newsfile Corp. - October 2, 2020) -  Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) be...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) between December 7, 2017 and Augu...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - September 24, 2020) - Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Odonate Therapeutics, Inc....

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - September 22, 2020) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Odonate Therapeutics, Inc. ("Odonate" or the "Com...

PRNewsWire - 4 months ago

NEW YORK, Sept. 21, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Odonate ...

Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)---- $ODT #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of securities of Odonate Therapeutics, Inc. (NASDAQ: ODT) has filed a class...

Newsfile Corp - 4 months ago

New York, New York--(Newsfile Corp. - September 18, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the sec...

PRNewsWire - 4 months ago

NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Odonate Therapeutics, ...

Business Wire - 4 months ago

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Odonate Therapeutics, ...

PRNewsWire - 4 months ago

NEW YORK, Sept. 16, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Odonate Therapeutics, Inc.

The Motley Fool - 4 months ago

A couple of factors appear to be at work after the company announced the pricing of a secondary stock offering.

Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of p...

Business Wire - 4 months ago

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of p...

Business Wire - 4 months ago

ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Odonate Therapeutics, Inc. (“Odonate” or the “Company”) (NASDAQ: ODT) complied with federal securities laws.

PRNewsWire - 4 months ago

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Odonate Therapeutics, Inc.

Benzinga - 5 months ago

Odonate Therapeutics (NASDAQ: ODT) shares were trading lower on Monday after the company announced the results from CONTESSA, a Phase 3 study of Tesetaxel, achieved the primary endpoint.

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of p...

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of p...

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Odonate Therapeutics (ODT) stock based on the movements in the options market lately.

Business Wire - 5 months ago

SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of p...

Zacks Investment Research - 7 months ago

Odonate Therapeutics (ODT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 9 months ago

Odonate Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Investment Research - 1 year ago

Odonate Therapeutics, Inc. (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Zacks Investment Research - 1 year ago

Studies have shown that a majority of successful stocks see acceleration in earnings before an uptick in the stock price.

Other stocks mentioned: BZH, NVAX, NVDA

About ODT

Odonate Therapeutics, a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with locally advanced or metastatic breast cancer; and CONTESSA 2 and CONTESSA TRIO, which is in Phase II clinical study for central nervous system metastases and various cancer treatments. The company was founded in 2013 and is based in San Diego, California.

Industry
Biotechnology
IPO Date
Dec 7, 2017
CEO
Kevin C. Tang
Employees
134
Stock Exchange
NASDAQ
Ticker Symbol
ODT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ODT stock is "Buy." The 12-month stock price forecast is 35.00, which is an increase of 73.10% from the latest price.

Price Target
$35.00
(73.10% upside)
Analyst Consensus: Buy